CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Find out which cards maximize cashback for loans. This introduction covers selection criteria and actionable steps for faster payoff.
20,272 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
As KBR prepares to unveil its Q4 2025 results, investors should focus on backlog, margins, and free cash flow. This g...
Retail investors may finally gain access to SpaceX’s IPO as account minimums being lowered promise a wider door. This...
Chinese shoppers are spending again, but not with the old urgency. A surge in savings and rising gold demand signals ...
Bitcoin, Ethereum, and XRP flashed potential buy signals after a wide market drop, according to on-chain analytics. A...
AI investing can feel crowded, but a pair of no-brainer artificial intelligence (ai) stocks stand out for durable gro...
As rate pressure persists, INDS faces mixed signals from its industrial and self-storage holdings. This dividend safe...
Unpack the essentials of fulgent genetics (flgt) earnings in plain language. This guide translates the earnings trans...
Broadcom faced a sharp earnings-driven selloff, tumbling about 14% in a single day. This article spotlights an under-...
Bitcoin faces a fresh warning from Wikipedia founder Jimmy Wales that BTC could drift toward lower levels, testing bu...
Starlink could change how we buy internet and phone services, and SpaceX's IPO adds a new layer of opportunity and ri...
CoreWeave delivered stronger top-line growth but a widening loss and cautious quarterly guidance. Investors reacted w...